About Event

As scientific knowledge advances and regulatory guidelines evolve, with Karuna and Lykos Therapeutics anticipating approvals in Q3, this is the year where the mental health treatment landscape changes thanks to the innovative development of brand new, next-generation neuropsychiatric drugs.

Join the 150+ industry leaders attending the 7th Neuropsychiatric Drug Development conference this September to transform knowledge, share cutting-edge advancements and foster pre-competitive collaboration to innovate precision psychiatry, propel next-generation drug R&D and fuel more clinical approvals

Join Your Peers to:

Hear from 30+ brand-new speakers from the likes of Janssen, Biogen, Sumitomo Pharma America, AbbVie, Lykos Therapeutics, Boehringer Ingelheim and Compass Pathways

Broaden your knowledge with specialized case studies covering PTSD, Behavioural Symptoms Associated with FTD, Substance Use Disorders, Bipolar and many more

Engage in 12+ hours of interactive workshop discussions spanning translational EEGs, behavioural and circuit-based in vivo models, efficacy of hallucinogens, and placebo-mitigating trial designs with Sage Therapeutics, Otsuka, Lundbeck, Gilgamesh, Delix and more

Participate in either the ‘Discovery & Preclinical’ or ‘Translational & Clinical’ track of the main conference days to ensure your time out of the office is completely relevant

Discover new next-generation targets, modalities, and technologies from 8+ new presenting companies including Karuna, Click, MapLight and Sensorium Therapeutics

Who You Will Meet?

Graph 1
Graph 2

Access the Comprehensive Event Guide With 35+ Speakers, 2 Tracks of Content, 4 Pre-conference Workshops & More!

Neuropsychiatric Drug Development

Why Industry Attends Neuropsychiatric Drug Development Summit:

“Very social and interactive sessions. Met lots of wonderful people. Felt like the topics were very relevant to my professional interests.”

Atai Life Sciences 

“Well-chosen speakers with late-breaking presentations that were informative and helpful.”

BioXcel Therapeutics 

“Great to have so many pharma experts reunited to discuss bottlenecks of neuropsychiatry R&D.”

Boehringer Ingelheim